Analysis Group to Present New Outcomes at 2026 ASCO Annual Meeting
Event:2026 ASCO Annual Meeting
Dates:
May 29–June 2, 2026
Location:
Chicago, IL/Online
Members of Analysis Group’s HEOR, Epidemiology & Market Access practice will present seven posters at the 2026 ASCO Annual Meeting. The program will feature a range of educational and scientific sessions on cancer research, treatment, and patient care.
Posters will be presented in Hall A of McCormick Place. Analysis Group poster presentations include:
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – May 30, 2026, 9:00 a.m.–12:00 p.m. CT
- “Real-world treatment patterns and overall survival (OS) in patients (pts) with HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinomas (mGEA) in the US,” coauthored by an Analysis Group team – including Managing Principal Keith Betts, Vice President Yan Wang, and Associates Shuang Wang and Ariel Chao – in collaboration with researchers from UC Irvine Health, Vanderbilt-Ingram Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, and Jazz Pharmaceuticals (sponsor).
Melanoma/Skin Cancers – May 31, 2026, 9:00 a.m.–12:00 p.m. CT
- “Long-term efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 5-year follow-up data,” coauthored by an Analysis Group team – including Vice Presidents Viviana García-Horton and Jenny Zhou, Associate Hannah Kim, and Senior Analysts Dana Christensen and Matthew Mattera – in collaboration with researchers from The University of Texas MD Anderson Cancer Center, the University of Essen and the German Cancer Consortium, The Sidney Kimmel Comprehensive Cancer Center, Massachusetts General Hospital, Istituto Nazionale Tumori IRCCS Fondazione Pascale, The Royal Marsden NHS Foundation Trust, Aix-Marseille University, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, and Bristol Myers Squibb (sponsor).
Hematologic Malignancies—Plasma Cell Dyscrasia – June 1, 2026, 9:00 a.m.–12:00 p.m. CT
- “Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): Updated matching-adjusted indirect comparison (MAIC) with longer follow-up,” coauthored by an Analysis Group team – including Vice Presidents Viviana García-Horton and Jenny Zhou, Manager Mirko Fillbrunn, and Senior Analysts Wenxin Ma and Matthew Mattera – in collaboration with researchers from the Sarah Cannon Research Institute, The Ohio State University Comprehensive Cancer Center, Icahn School of Medicine at Mount Sinai, Karmanos Cancer Institute, the University of Miami Health System, and Regeneron Pharmaceuticals (sponsor).
In addition, the following study has been accepted for online publication:
- “Real-world use of piflufolastat F 18 and imaging-associated treatment patterns in early-stage prostate cancer,” coauthored by an Analysis Group team, including Managing Principal Noam Kirson, Manager Christopher Yee, Associate Emma Billmyer, and Senior Analyst Zhou Chen.